05-03, 16:00–16:25 (Asia/Jerusalem), PyData Track 2
Immunai has built one of the largest centralized immune single-cell data assets in the world and is using AI with it to expand the boundary of our understanding of core immune biology and how it translates to the clinical setting.
Our ability to interrogate and decipher the immune system has dramatically improved over the last 5 years with major advances in single-cell multiomic technology, both in the wet lab and in silico. Immunai has built one of the largest centralized immune single-cell data assets in the world and is using it to expand the boundary of our understanding of core immune biology and how it translates to the clinical setting. But this massive data asset offers a unique challenge in how to understand individual cell types, patients, diseases and treatments in the context of all the others. Immunai tackles this problem with cutting-edge artificial intelligence coupled tightly with our functional genomics platform, which together identify core biological mechanisms that enable us to develop the next generation of immune system therapeutics.
English
Target audience –Data Scientists, R&D
Drausin Wulsin is the ML lead at Immunai. He holds a PhD in Bioengineering from the University of Pennsylvania and has spend the last 8 years in industry building data, software, & ML teams in high-growth tech companies.